|
Developing a Portfolio of Therapeutics to Combat the Rising Threat of Infectious Diseases
|
|
Infectious disease ranks as the third leading cause of death in the United States and the leading cause of death worldwide. The worldwide market for anti-infectives is estimated at over $50 billion with anti-bacterials representing the largest class of drugs in this market with annual sales in excess of $30 billion.
In addition, the emergence of diseases such as SARS and West Nile Virus, the increased resistance of organisms to existing therapies, combined with the increased prevalence of food-borne diseases such as E. coli:O157:H7 have highlighted the lack of effective therapeutics and/or vaccines to combat many of these diseases. In addition, many experts believe that it is only a matter of time before one of these more virulent pathogens becomes more readily transmissible to humans resulting in a worldwide pandemic or used as a bioterrorist weapon.
The opportunity for novel anti-infectives is massive, the need is unmet and the healthcare community is desperate for new therapeutics. Lakewood-Amedex is poised to capitalize on this opportunity and capture a leadership position in the development of novel pharmaceuticals for the treatment of a wide range of infectious disease.
|
|